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Abstract
Background: This study aimed to identify the health-related quality of life (HRQOL) domains associated with
prognosis by assessing longitudinal alterations in HRQOL in patients with advanced hepatocellular carcinoma
receiving sorafenib.
Methods: We prospectively assessed HRQOL by administering the SF-36 questionnaire 3-monthly to consecutive
patients with advanced hepatocellular carcinoma receiving sorafenib. We evaluated the impact of HRQOL on their
overall survival and duration of treatment with sorafenib using Cox's proportional hazards model.
Results: There were 54 participants: 42 (78 %) were male, the median age was 71 years, 24 (44 %) had hepatitis C
virus infection, 33 (61 %) had Child-Pugh scores of 5, and 30 (56 %) had TNM stage IV hepatocellular carcinoma.
The median overall survival and treatment duration were 9 and 5 months, respectively, and 40 patients (74 %) died.
Thirteen patients receiving sorafenib over a 1-year period maintained all domain scores >40, without a significant
decline during the treatment period. In contrast, physical functioning, physical role, and vitality scores declined
continuously and significantly in the year before death (in the 40 patients who died). Previous curative treatment
and physical functioning scores ≥40 at baseline were significantly associated with longer overall survival by
multivariate analysis. Social functioning scores ≥40, absence of vascular invasion, and lower DCP value were
significant predictors of longer treatment duration.
Conclusions: HRQOL was not significantly impaired in those patients who were able to complete a 1-year course of
sorafenib treatment. Baseline physical functioning scores ≥40 and social functioning scores ≥40 were significantly
associated with longer overall survival and longer treatment duration, respectively. Thus, HRQOL could be a valuable
marker to predict the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib.
Keywords: Advanced hepatocellular carcinoma, Sorafenib, Health-related quality of life, Clinical course, Prognostic
marker
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Background
Liver cancer is the third leading cause of cancer-related
deaths worldwide [1]. The prognosis of patients with he-
patocellular carcinoma (HCC) is poor because of the
high recurrence rate and/or the presence of underlying
chronic liver disease(s). Sorafenib, a small molecular in-
hibitor of several tyrosine protein kinases—vascular
endothelial growth factor receptor, platelet-derived
growth factor receptor, and Raf kinases—extends the
median overall survival by nearly 3 months compared
with placebo in patients with advanced HCC [2, 3].
However, adverse effects (such as hand-foot skin reac-
tions, diarrhea, or weight loss) and the deterioration in
liver function associated with its use, and progressive
disease, limit the efficacy of sorafenib.
Quality of life is a multi-dimensional concept that in-
cludes subjective evaluation of both physical and mental
aspects of life. More specifically, the term “health-related
quality of life” (HRQOL) refers to a multidimensional
concept that encompasses patients’ perceptions of both
negative and positive aspects of at least four dimensions:
physical functioning, emotional well-being, social well-
being, and spiritual well-being; and disease and treatment-
related symptoms. HRQOL assessment is becoming an
important component of health surveillance and an indi-
cator of service needs and intervention outcomes.
Furthermore, HRQOL could be used as a prognostic
marker for patients with various types of cancer [4]. In
particular, the baseline physical functioning domain has
been associated with survival in patients with non-small
cell lung cancer [5] and tumor-node-metastasis (TNM)
stages III and IV colorectal cancer [6]. A recent study
revealed that physical well-being, evaluated using the
Functional Assessment of Cancer Therapy-Hepatobiliary,
could be used as a prognostic marker in patients with vari-
ous stages of HCC and cholangiocarcinoma [7]. However,
few studies have explored the association of HRQOL and
prognosis in patients with HCC. Targeted molecular ther-
apy, now widely used for many types of cancers, is often
accompanied by unique adverse effects, such as hand-foot
skin reaction [8]. In terms of adverse effects, longitu-
dinal follow-up for HRQOL is likely to facilitate clinical
decision-making by correctly evaluating the patient’s
condition. Several studies have reported on changes in
HRQOL in patients receiving targeted molecular ther-
apy [9–12], but with controversial results. Sorafenib
treatment was associated with a significant decrease in
quality of life because of adverse effects in patients with
HCC [12, 13] and advanced renal cell carcinoma [12].
In contrast, Miyake et al. could not identify a signifi-
cant influence of sorafenib on HRQOL in patients with
metastatic renal cell carcinoma [9]. Therefore, further
evidence on the impact of sorafenib therapy on quality
of life and clinical course is required.
In this study, we aimed to clarify longitudinal alter-
ations in HRQOL in patients with advanced HCC [3]




We enrolled consecutive patients with advanced HCC
who received sorafenib therapy from August 4, 2010 to
April 7, 2015 at Tokai University Hospital. Eligibility cri-
teria were as follows: (1) non-resectable advanced HCC;
(2) resistance to, or no indication for, transcatheter arter-
ial chemoembolization; (3) Child-Pugh class A or B [14];
(4) TNM criteria of Liver Cancer Study Group of Japan
stage III or IV [15]; and (5) Eastern Cooperative Oncology
Group Performance Status (ECOG PS) 0 or 1 [16]. Most
patients received 800 mg of sorafenib as an initial dose,
but lower doses (including 200, 400, and 600 mg) were
administered to certain patients, particularly those aged >
70 years or with Child-Pugh class B liver function. Nurses
provided educational instructions when initiating sorafe-
nib treatment and gave medical advice by telephone.
Health-related quality of life assessment
We prospectively assessed HRQOL using a Japanese ver-
sion of the short form health survey (SF-36) v2™ [17].
We chose SF-36 because its Japanese national standard
score was available. Patients completed this question-
naire every 3 months by self-report during their clinic
visits. The questionnaire assessed eight domains for
health status, with 36 questions covering both mental
and physical aspects of health. These aspects included
physical functioning; role limitations because of physical
problems—referred to as role physical (RP); bodily pain;
general health; vitality; social functioning; role limita-
tions because of emotional problems—referred to as role
emotional (RE); and mental health. Each domain was
scored on a scale of 0–100, with lower scores indicating
poorer health status. A score of 50 points, considered
the Japanese national standard, was used for comparison
with study samples [17, 18]. In this study, we chose a
score of 40 points—80 % of the Japanese national stan-
dard—as the cut off value.
Clinical evaluation
Tumor measurements were performed using dynamic
computed tomography (CT) or magnetic resonance im-
aging (MRI) before and every 3 months after initiation
of sorafenib treatment. Assessment of disease control
and progression was based on the modified Response
Evaluation Criteria in Solid Tumors [19]. The disease
control rate was defined as the percentage of patients
with complete response, partial response, and stable
disease 3 months after initiation of sorafenib. Adverse
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events were evaluated monthly using National Cancer
Institute Common Toxicity Criteria (version 4.0) [20].
Patients were followed up until May 25, 2015 or death.
The discontinuation of sorafenib was defined as the out-
come for treatment duration in this study.
Statistical analysis
To analyze the changes in HRQOL scores, we used the
Friedman test, Bonferroni correction, and Wilcoxon
two-sample test for patients who continued sorafenib
treatment over a 1-year period, and the Kruskal-Wallis
or Mann-Whitney U test for the 40 deceased patients.
We analyzed the relationship between HRQOL, baseline
characteristics, overall survival, and treatment duration
using multiple logistic regression and Cox's proportional
hazards regression model. Multivariate analysis was per-
formed using the forward stepwise procedure (likelihood
ratio). We also analyzed treatment discontinuation inci-
dence using a competing risks approach (Gray’s method).
Medians and interquartile ranges (IQR) or means and
standard deviations were used to describe non-parametric
and parametric data, respectively. Categorical variables
were represented in terms of proportions and frequency
tables. P values < 0.05 were considered to indicate statis-
tical significance. Statistical analysis was performed using




Of the 54 patients participating in the study, 42
(78 %) were male (Table 1). The median age was
71 years (range, 57–84 years). Nearly half of the pa-
tients (44 %) had hepatitis C virus (HCV) infection.
Most patients (61 %) had a Child-Pugh score of 5
(median score: 5.0 IQR: 5.0–6.0), and most (57 %)
had TNM stage IV HCC. The majority of patients
(68 %) had received curative therapy, such as surgical
resection and radiofrequency ablation, before enrol-
ment to the study.
We analyzed the association between each HRQOL
domain score and patient characteristics at baseline.
Female sex was associated with lower physical function-
ing domain scores than male sex (OR 0.167, 95 % CI
0.039–0.715, p = 0.016). Patients aged < 70 years had
significantly lower scores in the domain of general
health (OR 0.280, 95 % CI 0.080–0.984, p = 0.047). Role
physical domain scores was significantly higher the pa-
tients with previous curative treatment (34.8 ± 11.5
[mean ± SD] points) than without (31.1 ± 17.3 points).
Other domain scores were not significantly different in
terms of baseline patient characteristics.
Treatment efficacy and adverse events
Disease control was obtained in 27 patients (50 %):
one (2 %) had complete response, five (9 %) had par-
tial response, and 21 (39 %) had stable disease. In
total, 40 patients (74 %) died. Almost all patients
(98 %) experienced adverse events (Additional file 1:
Figure S1). Common adverse events included anorexia
(76 %), skin toxicity (72 %), fatigue (63 %), diarrhea
(56 %), and weight loss (52 %). There were no grade
4 or 5 adverse effects. Grade 3 adverse effects oc-
curred in 27 patients (50 %). Of these, skin toxicity
was most common (33 %), followed by anorexia
(15 %) and fatigue (9 %). Sorafenib was discontinued
or the dose was reduced in 11 (20 %) and 16 patients
(30 %), respectively, because of adverse events. At the
end of observation period, sorafenib was withdrew in
42 patients. The reasons for withdrawal were as fol-
lows: disease progression (34 patients); adverse events
of skin toxicity and diarrhea (two patients); complica-
tions such as stroke, pneumonia, and intracranial
hemorrhage (three patients); and at the patient’s re-
quest (three patients).
























































DCP des-gamma-carboxy prothrombin, HCV hepatitis C virus, HBV hepatitis
B virus
aDCP values were not available for two cases
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Fig. 1 (See legend on next page.)
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Changes in HRQOL domain scores
Overall, 13 patients (24 %) were able to take sorafenib
over the course of at least 1 year. These patients main-
tained HRQOL domain scores >40 without any signifi-
cant decline (Additional file 1: Figure S2 and Table S2).
Domain scores were not significantly different between
patients who experienced grade 3 adverse effects and
those who did not (Additional file 1: Figure S3).
Next, we analyzed the changes in HRQOL domain
scores over the 12 months preceding death in the 40 pa-
tients who died (Fig. 1 and Additional file 1: Table S1).
The psychosocial and pain domains—including bodily
pain, general health, social functioning, and mental
health—did not demonstrate significant changes, but the
scores remained >40 points until imminent death. In
contrast, physical functioning, role limitations because
of physical problems, and vitality domain scores declined
continuously and significantly towards death.
The association of HRQOL domain scores and patient
characteristics with overall survival and treatment
duration
The median overall survival was 9.6 (IQR: 0.8–16.3)
months. Previous curative therapy and a physical func-
tioning domain score ≥40 at baseline were associated
(See figure on previous page.)
Fig. 1 Time-point comparison of changes in HRQOL domain scores in the 12 months prior to death. 12 months before, 12 months before death
(n = 8); 9 months before, 9 months before death (n = 4); 6 months before, 6 months before death (n = 22); 3 months before, 3 months before
death (n = 31); imminent death, less than 3 months before death (n = 40). * All values shown are median scores. ** Upper lines show statistically
significant differences using Mann-Whitney U test (P < 0.05). HRQOL, health-related quality of life
Table 2 Baseline demographic and clinical variables and baseline domain scores associated with overall survival
Variable Univariatea Multivariatea
HR (95 % CI) P HR (95 % CI) P
Baseline characteristics
Age <70 y (vs. ≥70 y) 0.603 (0.349–1.258) 0.208
Sex, male (vs. female) 0.544 (0.254–1.167) 0.118
HCV infection (vs. other etiology) 1.138 (0.610–0.122) 0.684
Child Pugh = 5 (vs. ≥6) 0.419 (0.227–0.812) 0.009
TMN stage III (vs. IV) 0.695 (0.371–1.304) 0.257
Vascular invasion - (vs. +) 0.475 (0.204–0.945) 0.034
Tumor size <50 mm (vs. ≥50 mm) 0.831 (0.441–1.567) 0.567
Previous curative therapy: Yes (vs. No) 0.255 (0.129–0.504) <0.001 0.235 (0.116–0.477) <0.001
AFP <100 (vs. ≥100) 0.893 (0.473–1.686) 0.726
DCP <1000 (vs. ≥1000) 0.548 (0.280–1.070) 0.078
Initial dose of sorafenib 800 mg (vs. <800 mg) 1.137 (0.611–2.115) 0.686
Treatment duration ≥5 months (vs. <5) 0.608 (0.325–1.138) 0.120
HRQOL domain scores ≥40b:
Physical functioning 0.529 (0.278–1.008) 0.053 0.479 (0.245–0.935) 0.031
Role physical 0.595 (0.314–1.127) 0.111
Bodily pain 1.686 (0.772–3.676) 0.190
General health 1.331 (0.644–2.755) 0.440
Vitality 0.842 (0.383–1.848) 0.669
Social functioning 0.833 (0.411–1.684) 0.610
Role emotional 0.957 (0.473–1.938) 0.904
Mental health 2.053 (0.893–4.717) 0.090
HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin, HRQOL
health related quality of life
aCox proportional hazards regression analysis
bAll domain scores are relative to scores <40
All variables with P values <0.06 in the univariate analysis were included in the multivariate analysis
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with longer overall survival by multivariate analysis
(Table 2 and Fig. 2).
Age, liver function (Child-Pugh score), and HCC stage
were not significantly associated with overall survival,
neither were serum alpha-fetoprotein or DCP levels. The
median duration of sorafenib treatment was 4.9 (IQR:
0.2–10.8) months. Social functioning domain scores ≥40
at baseline, absence of vascular invasion, and lower DCP
values were significant predictors for longer treatment
duration (Table 3 and Fig. 3). The association of social
functioning domain scores with treatment duration was
confirmed by the competing risk analysis (Additional
file 1: Figure S4).
Discussion
HRQOL was not significantly impaired in the patients
who could receive sorafenib treatment over the course
of 1 year (Additional file 1: Figure S2 and Table S2). A
previous study showed decreased HRQOL domain
scores in the 2 months after initiation of sorafenib in pa-
tients with advanced HCC because of adverse events
[13]. In contrast, sorafenib treatment did not signifi-
cantly affect HRQOL in patients with metastatic renal
cell carcinoma [9, 21]. We found no significant differ-
ences in HRQOL domain scores between patients who
experienced grade 3 adverse effects and those who did
not (Additional file 1: Figure S3). The severe adverse
effects associated with sorafenib use, reported to occur
in 50 % of patients [22], potentially influence HRQOL.
Interestingly, skin toxicity [23], hypertension [24], and
diarrhea [25] are known to be associated with better
prognosis in sorafenib therapy. Therefore, the substantial
anti-tumor effects of sorafenib might have countered se-
vere adverse effects both physically and mentally.
Within HRQOL, physical functioning, role limitations
because of physical problems (RP), and vitality domain
scores gradually decreased towards death. These declines
would have reflected the progression of HCC and the
deterioration of underlying liver diseases. This is the first
prospective long term follow-up study on HRQOL
scores in patients with advanced HCC receiving sorafenib
therapy. Interestingly, scores in the psychosocial HRQOL
domains—social functioning, role limitations because of
emotional problems (RE), and mental health—were main-
tained >40 points until death. The bodily pain score also
remained >40, suggesting that the psychosocial domains
and bodily pain can be managed well by periodical med-
ical and nursing interventions. Higher physical function-
ing domain scores at baseline were significantly associated
with longer overall survival. Our study also demonstrated
that physical functioning decreased significantly towards
death. Taken together with the results of Cox regression
analysis, physical functioning domain scores could be
good predictors of prognosis. These results are in accord-
ance with previous studies, which revealed better physical
functioning and role limitations because of physical prob-
lems as predictors for longer survival in patients with
non-resectable HCC [26] and in those requiring palliative
care for HCC [27]. Previous studies suggest that daily
physical activity contributes to the decrease in mortality
due to liver cancer [28, 29]. A prospective study is neces-
sary to verify whether adequate levels of physical activity
would improve the prognosis of HCC patients. Our study,
for the first time, showed that HRQOL domain scores
were useful to predict prognosis in patients with advanced
HCC receiving sorafenib. Thus, when we observe a de-
cline in physical functioning domain scores, we should
pay more careful attention to the patient’s condition.
These observations are supported by studies of frailty.
Frailty is significantly associated with depression [30]
and mortality [31] in patients with end-stage liver dis-
ease. The impact of frailty on mortality is evident in
elderly patients [32]. Given that the Japanese patients
with HCC are mostly geriatric (median age in this
study: 71 years old), the concept of frailty appears im-
portant to predict prognosis [33].
Higher social functioning domain scores at baseline
contributed to longer treatment duration. The social
functioning domain score might reflect social support
associated with adherence to sorafenib. Sufficient social
support from the beginning of sorafenib therapy would
be helpful to continue medication, which is potentially
accompanied by severe adverse effects. We also found
that the presence of vascular invasion and a DCP value
Fig. 2 Kaplan-Meier graphs displaying time-to-death stratified by factors
associated with overall survival: physical functioning (PF) scores
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>1000 mAU/mL were significant predictors of shorter
treatment duration. Tumors with vascular invasion [34]
or an associated high level of DCP [35] are likely to have
an aggressive phenotype.
Many studies associate preserved liver function with
better survival [36], however, Child-Pugh score as an
index of liver function was not chosen as a significant
predictor for overall survival in this study. The reason
for this discrepancy can be explained by the back-
ground of our cohort; liver function was well pre-
served in most patients (Child-Pugh score 5: 59 %,
score 6: 32 %, and score 7: 9 %).
Different etiologies can influence the interpretation of
the results of clinical studies. The major causes of HCC
in this cohort were HCV (44 %), HBV (20 %), and alco-
hol (13 %). A similar trend is seen in Europe and North
America [37], where the leading causes of HCC are
HCV (50–70 %), HBV (20–30 %), and alcohol (20 %).
Hence, our results could be applicable to such areas.
The presence of previous curative therapy was sig-
nificantly associated with better overall survival. The
Table 3 Baseline demographic and clinical variables and domain scores associated with treatment duration
Variables Univariatea Multivariatea
HR (95 % CI) P value HR (95 % CI) P value
Baseline characteristics
Age <70 y (vs. ≥70 y) 0.749 (0.343–1.429) 0.380
Sex, male (vs. female) 0.634 (0.307–1.308) 0.217
HCV infection (vs. other etiology) 1.796 (0.964–3.348) 0.065
Child Pugh = 5 (vs. ≥6) 0.511 (0.271–0.962) 0.038
TMN stage III (vs. IV) 0.672 (0.357–1.264) 0.218
Vascular invasion – (vs. +) 0.355 (0.178–0.710) 0.003 0.382 (0.186–0.786) 0.009
Tumor size <50 mm (vs. ≥50 mm) 0.777 (0.412–1.466) 0.432
Previous curative therapy: Yes (vs. No) 0.433 (0.226–0.829) 0.012
AFP <100 (vs. ≥100) 1.048 (0.561–1.961) 0.954
DCP <1000 (vs. ≥1000) 0.473 (0.509–0.912) 0.025 0.509 (0.261–0.993) 0.048
Initial dose of sorafenib 800 mg (vs. <800 mg) 0.744 (0.388–1.426) 0.373
HRQOL domain scores ≥40:b
Physical functioning 0.956 (0.509–1.799) 0.889
Role physical 0.771 (0.416–1.429) 0.408
Bodily pain 1.582 (0.728–3.436) 0.247
General health 1.034 (0.516–2.070) 0.926
Vitality 1.534 (0.631–3.731) 0.346
Social functioning 0.395 (0.185–0.840) 0.016 0.452 (0.206–0.995) 0.049
Role emotional 0.898 (0.455–1.770) 0.755
Mental health 0.833 (0.379–1.828) 0.649
HR hazard ratio, CI confidence interval, HCV hepatitis C virus, TNM tumor-node-metastasis, AFP alpha fetoprotein, DCP des-gamma-carboxy prothrombin; HRQOL,
health related quality of life
aCox proportional hazards regression analysis
bAll domain scores are relative to scores <40
All variables with P values <0.05 in the univariate analysis were included in the multivariate analysis
Fig. 3 Kaplan-Meier graphs displaying treatment duration stratified
by social functioning (SF) scores
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difference in the biological nature of tumors may ex-
plain these results. Tumors that recur after curative
treatment may be less aggressive than other tumors.
There are some limitations to this study. Although the
study was prospective, it was conducted in a single insti-
tution with a relatively small number of patients. The
initial dose of sorafenib used in our study was 800 mg,
but lower doses were used for some elderly patients.
Thus, initial doses were relatively low compared with
those used in a previous study [38]. However, the initial
dose did not affect prognosis in the present study.
Nevertheless, we cannot deny a potential influence of
initial sorafenib dose on overall survival and treatment
duration.
Conclusions
In conclusion, HRQOL was not significantly impaired in
patients who could receive sorafenib treatment over the
course of 1 year. Physical functioning scores ≥40 and
social functioning scores ≥40 at baseline were signifi-
cantly associated with longer overall survival and longer
treatment duration, respectively. Thus, HRQOL could
be a valuable marker to predict the clinical course of
patients with advanced HCC receiving sorafenib.
Additional file
Additional file 1: Table S1. Changes in HRQOL domain scores in the
12 months prior to death. Table S2. Changes in HRQOL domain scores in
patients who survived >1 year (n = 13). Figure S1. Graphical display of
the distribution of sorafenib-related adverse events (n = 54). Figure S2.
Graphical representation of HRQOL domain score changes of patients
receiving sorafenib over the course of one year (n = 13). Figure S3.
Graphical representation of HRQOL domain score changes with/without
grade 3 adverse events. Figure S4. Cumulative discontinuation incidence
curves stratified by factors associated with treatment duration: social
functioning (SF) scores. (DOCX 553 kb)
Abbreviations
AFP: Alpha fetoprotein; BP: Bodily pain; CT: Computed tomography;
DCP: Des-gamma-carboxy prothrombin; GH: General health;
HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; HRQOL: Health-related
quality of life; IQR: Interquartile range; MH: Mental health; MRI: Magnetic
resonance imaging; PF: Physical functioning; RE: Role emotional; RP: Role
physical; SF: Social functioning; TNM: Tumor-node-metastasis; VT: Vitality
Acknowledgements
We express our thanks to all patients who took part in this clinical research.
We thank all the members of Department Nursing Tokai University Hospital
for discussion and comments.
Funding
Shomura M received a JSPS KAKENHI Grant-in-Aid for Scientific Research (C)
25463445 from 2012 to 2016.
Availability of data and materials
All data related to this study are present in the manuscript.
Authors’ contributions
MS and TK contributed equally to this study. MS, TK, KS, SH, YA, and KT
provided sorafenib therapy to the patients; TK, KS, SH, YA, and KT, and TM
evaluated the efficacy of therapy; MS, TK, HO, and ST collected patients’ data,
performed the statistical analysis, and were involved in writing and editing
the manuscript; MS designed the study and provided financial support for
this work. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki
(2013) of the World Medical Association. The Institutional Review Board of
Tokai University (NO.10R-046) approved the study. All patients provided
written informed consent.
Précis
HRQOL was not significantly impaired in patients who received sorafenib
treatment over the course of one year. Certain HRQOL domains could be a
valuable marker to predict the clinical course of HCC patients receiving
sorafenib.
Author details
1Department of Nursing, Tokai University School of Health Sciences, Isehara,
Kanagawa, Japan. 2Division of Gastroenterology, Department of Internal
Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan.
3University of Nagasaki Department of Nursing, Nagasaki, Nagasaki, Japan.
4143 Shimokasuya, Isehara-city, Kanagawa 259-1193, Japan.
Received: 27 April 2016 Accepted: 28 October 2016
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced hepatocellular
carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009;10:25–34. doi:10.1016/s1470-2045(08)70285-7.
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, SHARP
Investigators Study Group, et al. Sorafenib in advanced hepatocellular
carcinoma. N Engl J Med. 2008;359:378–90. doi:10.1056/NEJMoa0708857.
4. Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life
scores: an independent prognostic variable in a general population of
cancer patients receiving chemotherapy. The National Cancer Institute of
Canada Clinical Trials Group. Qual Life Res. 1997;6:151–8.
5. Braun DP, Gupta D, Staren ED. Quality of life assessment as a predictor of
survival in non-small cell lung cancer. BMC Cancer. 2011;11:353. doi:10.1186/
1471-2407-11-353.
6. Braun DP, Gupta D, Grutsch JF, Staren ED. Can changes in health related
quality of life scores predict survival in stages III and IV colorectal cancer?
Health Qual Life Outcomes. 2011;9:62. doi:10.1186/1477-7525-9-62.
7. Steel JL, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, et al.
Health-related quality of life as a prognostic factor in patients with
advanced cancer. Cancer. 2014;120:3717–21. doi:10.1002/cncr.28902.
8. Grunwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. Molecular
targeted therapies for solid tumors: management of side effects. Onkologie.
2009;32:129–38. doi:10.1159/000194949.
9. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue TA, et al.
Impact of sorafenib on health-related quality of life in Japanese patients
with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010;
106:1643–7. doi:10.1111/j.1464-410X.2010.09437.x.
10. Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-
related quality of life during treatment for renal cell carcinoma: results from
a phase II study of axitinib. Acta Oncol. 2008;47:843–51. doi:10.1080/
02841860802047395.
11. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de
Braud F, et al. Health-related quality of life impact in a randomised phase III
study of the combination of dabrafenib and trametinib versus dabrafenib
monotherapy in patients with BRAF V600 metastatic melanoma. Eur J
Cancer. 2015;51:833–40. doi:10.1016/j.ejca.2015.03.004.
Shomura et al. BMC Cancer  (2016) 16:878 Page 8 of 9
12. Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The
effect of hand-foot skin reaction associated with the multikinase inhibitors
sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol.
2012;11:e61–5.
13. Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, et al.
Sorafenib in hepatocellular carcinoma: prospective study on adverse events,
quality of life, and related feasibility under daily conditions. Med Oncol.
2013;30:345. doi:10.1007/s12032-012-0345-2.
14. Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of
MELD and Child-Pugh score accuracies for the prediction of 6-month
mortality in cirrhotic patients. J Clin Gastroenterol. 2009;43:580–5.
doi:10.1097/MCG.0b013e3181889468.
15. Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of
hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC
TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:
909–22. doi:10.1097/01.sla.0000254368.65878.da.
16. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al.
Toxicity and response criteria of the Eastern Cooperative Oncology Group.
Am J Clin Oncol. 1982;5:649–55.
17. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation,
and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol.
1998;51:1037–44.
18. Fukuhara S, Ware Jr JE, Kosinski M, Wada S, Gandek B. Psychometric and
clinical tests of validity of the Japanese SF-36 health survey. J Clin
Epidemiol. 1998;51:1045–53.
19. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for
hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-
0030-1247132.
20. Japan Clinical Oncology Group. Common Terminology Criteria for Adverse
Events (CTCAE) v4.0-Japan Clinical Oncology Group. 2009. Available at http://
www.jcog.jp/doctor/tool/CTCAEv4J_20160310.pdf. Accessed 25 Mar 2016.
21. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms
and quality of life: results from a large randomized placebo-controlled study
in renal cancer. Am J Clin Oncol. 2007;30:220–7. doi:10.1097/01.coc.
0000258732.80710.05.
22. Koldenhof JJ, Witteveen PO, de Vos R, Walraven M, Tillier CN, Verheul HM, et
al. Symptoms from treatment with sunitinib or sorafenib: a multicenter
explorative cohort study to explore the influence of patient-reported
outcomes on therapy decisions. Support Care Cancer. 2014;22:2371–80.
doi:10.1007/s00520-014-2223-2.
23. Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, et al. Skin
toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular
carcinoma. World J Hepatol. 2014;6:670–6. doi:10.4254/wjh.v6.i9.670.
24. Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma:
hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol.
2007;36:319–24. doi:10.1097/COC.0b013e3182468039.
25. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM.
Diarrhea is a positive outcome predictor for sorafenib treatment of
advanced hepatocellular carcinoma. Oncology. 2013;84:6–13. doi:10.1159/
000342425.
26. Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, et al. Quality of life is
predictive of survival in patients with unresectable hepatocellular
carcinoma. Ann Oncol. 2006;17:1083–9. doi:10.1093/annonc/mdl065.
27. Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, et al. The added
value of quality of life (QoL) for prognosis of overall survival in patients with
palliative hepatocellular carcinoma. J Hepatol. 2013;58:509–21. doi:10.1016/j.
jhep.2012.11.019.
28. Behrens G, Matthews CE, Moore SC, Freedman ND, McGlynn KA, Everhart JE, et
al. The association between frequency of vigorous physical activity and
hepatobiliary cancers in the NIH-AARP Diet and Health Study. Eur J Epidemiol.
2013;28:55–66. doi:10.1007/s10654-013-9767-1.
29. Ukawa S, Tamakoshi A, Wakai K, Kurozawa Y. Associations of daily walking
and television viewing time with liver cancer mortality: findings from the
Japan Collaborative Cohort Study. Cancer Causes Control. 2014;25:787–93.
doi:10.1007/s10552-014-0380-8.
30. Cron DC, Friedman JF, Winder GS, Thelen AE, Derck JE, Fakhoury JW, et al.
Depression and frailty in patients with end-stage liver disease referred for
transplant evaluation. Am J Transplant. 2016;16:1805–11. doi:10.1111/ajt.13639.
31. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts
waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:
1870–9. doi:10.1111/ajt.12762.
32. Chang SF, Lin PL. Frail phenotype and mortality prediction: a systematic
review and meta-analysis of prospective cohort studies. Int J Nurs Stud.
2015;52:1362–74. doi:10.1016/j.ijnurstu.2015.04.005.
33. Gill TM, Gahbauer EA, Han L, Allore HG. Trajectories of disability in the last
year of life. N Engl J Med. 2010;362:1173–80. doi:10.1056/NEJMoa0909087.
34. Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival
of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by
the extent of portal vein invasion and the type of extrahepatic spread. PLoS
One. 2015;10, e0124434. doi:10.1371/journal.pone.0124434.
35. Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, et al.
Evaluation of the effect of sorafenib using serum NX-des-γ-
carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res.
2013;43:1064–70.
36. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, et al.
Development and validation of a new prognostic system for patients with
hepatocellular carcinoma. PLoS Med. 2016;13, e1002006. doi:10.1371/journal.
pmed.1002006.
37. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;31(379):
1245–55. doi:10.1016/S0140-6736(11)61347-0.
38. Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, et
al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a
case series. Oncology. 2013;84:265–72. doi:10.1159/000345558.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Shomura et al. BMC Cancer  (2016) 16:878 Page 9 of 9
